^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

everolimus

i
Company:
Generic mfg.
Drug class:
mTOR inhibitor
Related drugs:
2d
RAD001-mediated mTOR targeting in human monocyte-derived dendritic cells shifts them toward an immunogenic phenotype. (PubMed, Immunol Res)
Taken together, our findings indicated that RAD001 treatment of DCs can be a promising therapeutic approach for the generation of immunogenic DCs in order to barricade tumor growth. However, there is a need for further investigation to evaluate the impacts of mTOR inhibition by RAD001 in DCs on cellular immune responses in vitro and in vivo.
Journal • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • ITGAX (Integrin Subunit Alpha X)
|
IDO1 expression
|
everolimus
4d
Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine. (PubMed, Discov Oncol)
Chemotherapy includes the use of doxorubicin or taxanes generally with platinum-based drugs viz. cisplatin or carboplatin that are administered alone or along with multitarget tyrosine kinase inhibitors viz. Lenvatinib, Sorafenib, Sunitinib, Vandetanib, Pyrazolo-pyrimidine compounds, etc., single target tyrosine kinase inhibitors like Dabrafenib plus Trametinib and Vemurafenib against BRAF, Gefitinib against EGFR, Everolimus against mTOR, vascular disruptors like Fosbretabulin, and immunotherapy with viz. Spartalizumab and Pembrolizumab, are anti-PD-1/PD-L1 molecules...Hence, our review presents a closer view of NDDS as a personalized treatment for TC. We have also discussed the primary challenges facing NDDS in meeting excellence in PM.
Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
|
Keytruda (pembrolizumab) • Mekinist (trametinib) • cisplatin • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • carboplatin • gefitinib • sorafenib • sunitinib • everolimus • Lenvima (lenvatinib) • doxorubicin hydrochloride • Caprelsa (vandetanib) • spartalizumab (PDR001) • Zybrestat (fosbretabulin)
4d
An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus (clinicaltrials.gov)
P2, N=80, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
everolimus
4d
High MICAL-L2 promotes cancer progression and drug resistance in renal clear cell carcinoma cells through stabilization of ACTN4 following vimentin expression. (PubMed, Biochim Biophys Acta Mol Basis Dis)
Overexpression of MICAL-L2 stimulated cell migration, proliferation, and rendered KIRC cells insensitive to sunitinib and everolimus, two traditional therapies for KIRC. Furthermore, MICAL-L2 overexpression accelerated cancer progression and resistance to therapy in KIRC cells by interacting with its downstream regulator α-actinin-4 (ACTN4) in a Rab13-dependent manner, which reduced the degradation of ACTN4, leading to increased Vimentin expression. All these findings indicate that MICAL-L2 plays a crucial role in the progression of KIRC and suggest that MICAL-L2 may serve as a potential therapeutic target for KIRC treatment.
Journal
|
VIM (Vimentin)
|
VIM expression
|
sunitinib • everolimus
4d
Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor-Positive Advanced Breast Cancer. (PubMed, JCO Oncol Pract)
This extensive data pool suggests significant benefit of CDK4/6i regimens after disease progression as compared with ET monotherapy. Our data also support current guideline recommendations of ET-based therapies over chemotherapy for treatment sequencing.
Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • EGFR positive
|
everolimus
9d
Targeting HIF-2α: the role of belzutifan in clear cell renal carcinoma management. (PubMed, Expert Rev Clin Pharmacol)
The LITESPARK-005 trial reported the benefit of belzutifan in progression-free survival (PFS) compared to everolimus in later lines of treatment, with improvement in quality-of-life outcomes. Given its different mechanism of action to currently available treatments, belzutifan is expected to play a prominent role in the treatment of clear cell renal carcinoma and other cancers.
Review • Journal
|
EPAS1 (Endothelial PAS domain protein 1)
|
everolimus • Welireg (belzutifan)
10d
New P2 trial • Metastases
|
everolimus
12d
Emerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review. (PubMed, Medicine (Baltimore))
Gliomas are tumors arising in the central nervous system, frequently associated with Class I mutations and BRAF fusions. Further research into resistance mechanisms and long-term effects is necessary to optimize treatment strategies. Other therapies, such as everolimus and Selumetinib, also show potential and warrant further investigation.
Review • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600 • BRAF fusion
|
Mekinist (trametinib) • Tafinlar (dabrafenib) • everolimus • Koselugo (selumetinib)
12d
MTOR Inhibitors in Older Adults (clinicaltrials.gov)
P1/2, N=60, Not yet recruiting, University of Texas Southwestern Medical Center
New P1/2 trial
|
CRP (C-reactive protein)
|
everolimus • sirolimus
12d
ADELA: Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (clinicaltrials.gov)
P3, N=240, Recruiting, MedSIR | Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> Dec 2024
Enrollment open • Trial initiation date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
|
HER-2 mutation • ER mutation
|
everolimus • dexamethasone • Orserdu (elacestrant)
12d
Imlunestrant is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wildtype and Mutant Breast Cancer. (PubMed, Cancer Res)
While anti-estrogens that degrade ERα (fulvestrant) or block estrogen production (aromatase inhibitors) have improved patient outcomes, clinically important challenges remain related to drug administration, limited bioavailability, lack of brain exposure, and acquired resistance due to ESR1 mutations...Combining imlunestrant with abemaciclib (CDK4/6 inhibitor), alpelisib (PI3K inhibitor), or everolimus (mTOR inhibitor) further enhanced tumor growth inhibition, regardless of ESR1 mutational status. In an ER+ breast cancer intracranial tumor model, imlunestrant prolonged survival compared to vehicle or alternative SERD therapies. Together, these finding support the potential of imlunestrant to degrade ERα and suppress the growth of ESR1 wildtype and mutant breast cancer, including brain metastatic tumors.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 negative • ER mutation
|
everolimus • Piqray (alpelisib) • Verzenio (abemaciclib) • fulvestrant • imlunestrant (LY3484356)
16d
AMEERA-1: Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer (clinicaltrials.gov)
P1/2, N=136, Terminated, Sanofi | Trial completion date: Dec 2027 --> Nov 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2027 --> Nov 2024; Sponsor decision to prematurely stop the study, not linked to any safety concern.
Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
Ibrance (palbociclib) • everolimus • Piqray (alpelisib) • Verzenio (abemaciclib) • amcenestrant (SAR439859)
16d
Trial initiation date • Metastases
|
everolimus • fulvestrant • exemestane • SCR-6852
17d
IDUNN: Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy (clinicaltrials.gov)
P3, N=210, Recruiting, medac GmbH | Trial completion date: Dec 2027 --> Aug 2030 | Trial primary completion date: Dec 2025 --> Aug 2027
Trial completion date • Trial primary completion date • Stroma
|
everolimus • Jakafi (ruxolitinib)
20d
MANTA: A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer (clinicaltrials.gov)
P2, N=333, Completed, Queen Mary University of London | Unknown status --> Completed
Trial completion • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • HER-2 negative + ER positive
|
everolimus • fulvestrant • vistusertib (AZD2014)
23d
Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
P1, N=214, Active, not recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • HER-2 negative + ER positive
|
Ibrance (palbociclib) • everolimus • SCR-6852
23d
Enrollment open • Metastases
|
everolimus • fulvestrant • exemestane • SCR-6852
24d
Autoimmune hepatitis: Towards a personalized treatment. (PubMed, World J Hepatol)
Cyclosporin A, a calcineurin inhibitor that decreases T cell activation, has proven effective for induction of remission, but its long-term side effects limit its appeal for maintenance...Sirolimus and everolimus have interesting effects on regulatory T cell populations and may become viable options in the future. Mycophenolate mofetil is not effective for induction but is a valid alternative for patients who are intolerant to azathioprine. B cell-depleting drugs, such as rituximab and belimumab, have been successfully used in refractory cases and are useful in both the short and long term. Other promising treatments include anti-tumor necrosis factors, Janus kinases inhibitors, and chimeric antigen receptor T cell therapy. This growing armamentarium allows us to imagine a more tailored approach to the treatment of autoimmune hepatitis in the near future.
Review • Journal
|
TNFA (Tumor Necrosis Factor-Alpha)
|
Rituxan (rituximab) • everolimus • sirolimus • cyclosporin A microemulsion
25d
Treatment of Melanoma Cells with Chloroquine and Everolimus Activates the Apoptosis Process and Alters Lipid Redistribution. (PubMed, Int J Mol Sci)
The combination of mTOR inhibitors and chloroquine represents a promising area of research in cancer therapy. It has the potential to enhance treatment efficacy through complementary mechanisms.
Journal
|
CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
everolimus • chloroquine phosphate
30d
Massive simultaneous hepatic and renal perivascular epithelioid cell tumor benefitted from surgery and everolimus treatment: A case report. (PubMed, World J Gastrointest Surg)
Surgical treatment is preferred for malignant PEComa affecting liver and kidney, especially with TSC; everolimus is effective postoperatively.
Journal • Surgery
|
TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • FAT2 (FAT Atypical Cadherin 2) • MLANA (Melan-A) • TP73 (Tumor Protein P73)
|
everolimus
1m
Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: a multicenter real-world study. (PubMed, Ther Adv Med Oncol)
Internal validation cohort (PFS 18.4 vs 3.1 months, p = 3.6e-11, HR = 3.78, 95% CI = 2.49-5.74) and external validation cohort (PFS 13.5 vs 3.1 months, p = 2.9e-10, HR = 11.53, 95% CI = 4.68-28.37) confirmed its power for estimating clinical benefits of everolimus. A predictive model was successfully established to predict survival outcomes for everolimus in patients with HR+/HER2- ABC, which may provide references for the management of everolimus in Chinese patients with HR+/HER2- ABC.
Clinical • Journal • Real-world evidence • Predictive model • Real-world • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
everolimus
1m
Role of Immunotherapy in Conjunction With the Surgical Treatment of Breast Cancer: Preoperative and Postoperative Applications. (PubMed, Cureus)
Fourteen different articles showed that the use of cytokines and cancer vaccines revealed new possibilities to treat breast cancer with antibodies against PD-1/PD-L1 (pembrolizumab), PI3K/Akt/mTOR (alpelisib and everolimus), CAR T-cell (chimeric antigen receptor), PARP (poly ADP-ribose polymerase), and CTLA4 (cytotoxic T-lymphocyte-associated protein 4), and with representative relevance of changing in tumor microenvironment. Estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) targets show also a high effectivity. In recent years, the release of new strategies has become promising, for changing the microenvironment and de-escalation of therapy based on tumor biology, novel biomarkers, and tumor spread.
Review • Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
|
Keytruda (pembrolizumab) • everolimus • Piqray (alpelisib)
1m
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study. (PubMed, Eur J Cancer)
Endocrine therapy plus CDK 4/6i represents an effective treatment, regardless of HER2 status (low/zero). Second-line agents did not differ significantly in terms of TTD. Endocrine resistant cancers exhibit poor response to CDK 4/6i.
Journal • Real-world evidence • Real-world • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
|
everolimus • capecitabine • fulvestrant • exemestane
1m
TNO155 is a selective SHP2 inhibitor to target PTPN11-dependent oral squamous cell carcinoma. (PubMed, Heliyon)
However, whilst targeting EGFR with cetuximab has been approved for the treatment of OSCC, other single-agent inhibitors of the RTKs have shown modest effects in improving survival. In summary, PTPN11 is a promising therapeutic target in OSCC that can be selectively targeted by SHP2 inhibitor such as TNO155. Our findings on the use of mTOR inhibitor, everolimus to overcome resistance to TNO155 are essential to inform on next phases of clinical trials which is warranted for the treatment of OSCC.
Journal
|
EGFR (Epidermal growth factor receptor) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
PTPN1 overexpression
|
Erbitux (cetuximab) • everolimus • batoprotafib (TNO155)
1m
Successful Targeting of Somatic VHL Alterations With Belzutifan in Two Cases. (PubMed, J Immunother Precis Oncol)
The phase 3 clinical trial LITESPARK-005-belzutifan (HIF-2α inhibitor) demonstrated improvement in progression-free survival compared with everolimus in heavily pretreated patients unselected for somatic/germline VHL alterations (an objective response rate of 23% and a median time on therapy of 7.6 months in the belzutifan cohort), resulting in U.S. FDA approval for patients with advanced RCC. Both patients had an excellent clinical response (partial remissions ongoing at >12 and >20 months). Future studies should assess the merits of biomarker selection for belzutifan treatment.
Journal • IO biomarker
|
VHL (von Hippel-Lindau tumor suppressor) • EPAS1 (Endothelial PAS domain protein 1)
|
VHL mutation
|
everolimus • Welireg (belzutifan)
1m
Hypoxia drives CBR4 down-regulation promotes gastroenteropancreatic neuroendocrine tumors via activation mammalian target of rapamycin mediated by fatty acid synthase. (PubMed, J Cell Commun Signal)
In present study, we find that hypoxia promoted the methylation degree of CBR4 promoter region thus downgraded the expression of CBR4, which promoted GEP-NETs progression and increased the sensitivity of GEP-NETs cells to everolimus. Further, CBR4 interacted with fatty acid synthase (FASN), displaying a down-regulation of FASN by activating the ubiquitin proteasome pathway and suppressed mTOR signaling. Overall, our results uncovers the CBR4/FASN/mTOR axis as a mechanism for tumor development and inspires us a new molecular guide for the therapeutic strategies for GEP-NETs treatment.
Journal
|
mTOR (Mechanistic target of rapamycin kinase) • FASN (Fatty acid synthase)
|
everolimus
1m
Real-world outcomes of everolimus-based treatment in a Taiwanese cohort with metastatic HR+/HER2- breast cancer. (PubMed, J Chin Med Assoc)
These findings support current guidelines and advocate for the inclusion of everolimus in treatment plans for patients with metastatic HR+/HER2- breast cancer, particularly in late-line treatment, with careful consideration of the benefit-risk profile for each patient.
Journal • Real-world evidence • Real-world • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
everolimus
1m
Itacitinib + Everolimus in Hodgkin Lymphoma (clinicaltrials.gov)
P1/2, N=23, Active, not recruiting, University of Pennsylvania | Trial primary completion date: Oct 2024 --> May 2024
Trial primary completion date
|
everolimus • itacitinib (INCB039110)
1m
New P1/2 trial
|
cisplatin • carboplatin • paclitaxel • everolimus • Stivarga (regorafenib) • etoposide IV • SYHA1813
1m
New P3 trial • Metastases
|
everolimus • fulvestrant • exemestane • SCR-6852
2ms
First and Second-line Treatments in Metastatic Renal Cell Carcinoma. (PubMed, Eur Urol)
For optimal mRCC treatment selection, clinicians must carefully balance efficacy, toxicity, and patient preferences, especially when transitioning between first- and second-line therapies, to provide individualized care.
Review • Journal • IO biomarker • Metastases
|
EPAS1 (Endothelial PAS domain protein 1)
|
everolimus
2ms
Cancer Pathway Connectivity Resolved By Drug Perturbation and RNA Sequencing (ASH 2024)
We selected 108 CLL patient samples with genetic annotation and exposed them ex-vivo to small-molecule inhibitors used clinically (ibrutinib/BTKi, duvelisib/PI3Ki, trametinib/MEKi, everolimus/mTORi, selinexor/XPO1i) or targeting key signaling pathways (compound 26/TLRi, MK2206/AKTi, nutlin-3a/MDM2i, IBET872/BETi) for 48h. In conclusion, the addition of targeted pathway perturbations to the GEP of primary CLL samples can greatly enhance the potential for molecular and functional classification of disease and subgroups. Our study provides a blueprint to use perturbed omics profiling and interaction testing to link disease drivers to pathway activation and function.
IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • TNFA (Tumor Necrosis Factor-Alpha)
|
TS 12
|
BluePrint
|
Mekinist (trametinib) • Imbruvica (ibrutinib) • everolimus • Xpovio (selinexor) • MK-2206 • Copiktra (duvelisib)
2ms
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
P1, N=20, Recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Sep 2026
Trial completion date • Trial primary completion date • Metastases
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • everolimus • Lenvima (lenvatinib) • Cabometyx (cabozantinib tablet)
2ms
Extreme ESR1 polyclonality, mutational dynamics and effects on treatment outcomes in patients with ER+ metastatic breast cancer (SABCS 2024)
In 1 pt, eribulin and abraxane did not have the same effect; ESR1 polyclonality was maintained. One pt with 1 ESR1 clone after 2.5 years of fulvestrant+palbociclib developed 15 additional clones after 1.5 years of an experimental SERD+everolimus. Another pt with 1 ESR1 clone after anastrozole+palbociclib developed 9 additional ESR1 clones after 10 months of AKT inhibition+anastrozole... This is the first investigation of dynamic changes in extreme ESR1 polyclonality in association with treatment outcomes in pts with ER+ MBC. Capecitabine was associated with a decrease in detectable ESR1-mutant clones, while increased polyclonality was found at progression on SERD+everolimus, AKT-inhibitor+AI, and an ADC. Although extreme ESR1 polyclonality is rare, understanding mutational dynamics will improve our understanding of polyclonality more broadly and its impact on treatment resistance.
Clinical • Tumor mutational burden • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • TMB (Tumor Mutational Burden) • FGFR1 (Fibroblast growth factor receptor 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CCND1 (Cyclin D1)
|
TP53 mutation • PIK3CA mutation • ER mutation • ER Y537S • ER Y537N
|
Guardant360® CDx
|
Ibrance (palbociclib) • everolimus • capecitabine • albumin-bound paclitaxel • fulvestrant • Halaven (eribulin mesylate) • anastrozole
2ms
A case of sequential alpelisib and capivasertib in a patient with metastatic breast cancer harboring both a PIK3CA and AKT mutations (SABCS 2024)
Therapies targeting mutations in this pathway approved in conjunction with endocrine therapy include alpelisib, everolimus and capivasertib...She received nab-paclitaxel/atezolizumab for 4 months, letrozole and abemaciclib for 2 months, letrozole alone for 6 months, and letrozole and ribociclib for 6 weeks. Given presence of PIK3CA mutation, 4th line treatment with fulvestrant and alpelisib was planned...After progressing on capecitabine after 2 months, alpelisib with exemestane was initiated...Due to a low ejection fraction despite work with cardiooncology, she was not a candidate for trastuzumab deruxtecan. She progressed on oral cyclophosphamide and methotrexate after 2 months and Sacituzumab govitecan after 3 months...Comprehensive biomarker assessment is needed to identify patients who may benefit from sequential therapies. There is a need for trials comparing therapies that target the PI3K pathway at distinct points, potential sequencing of these therapies, and the optimal sequence strategy.
Clinical • PD(L)-1 Biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
|
ER positive • HR positive • PIK3CA mutation • PIK3CA E545K • AKT1 E17K • AKT1 mutation • PIK3CA E545 • PGR negative
|
Guardant360® CDx • MSK-IMPACT
|
Tecentriq (atezolizumab) • everolimus • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Piqray (alpelisib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Kisqali (ribociclib) • fulvestrant • Truqap (capivasertib) • methotrexate • letrozole • Trodelvy (sacituzumab govitecan-hziy) • exemestane
2ms
Rising ESR1 Mutations in Circulating Tumor DNA (ctDNA) Mediate Endocrine Therapy (ET) Resistance to Everolimus and ET but Retain Sensitivity to Fulvestrant in HR+/HER2- Metastatic Breast Cancer (MBC) (SABCS 2024)
None of the patients received ESR1-targeted therapy with Elacestrant. Our findings indicate that the level changes of ctDNA ESR1 mutations have implications with regards to treatment sensitivity and resistance to various therapies in patients with HR+/HER2- mBC. These results suggest a potentially effective method for monitoring treatment response and guiding future therapy by providing new insights into targeting ESR1 pathways to overcome resistance.
Circulating tumor DNA • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
HER-2 negative • PIK3CA mutation • HER-2 mutation • ER mutation • ER Y537S • ER D538G • ER Y537N
|
Guardant360® CDx
|
everolimus • fulvestrant • Orserdu (elacestrant)
2ms
Trial completion date
|
Keytruda (pembrolizumab) • sunitinib • everolimus • Lenvima (lenvatinib)
2ms
Enrollment open • Metastases
|
everolimus • fulvestrant • exemestane • Welireg (belzutifan)
2ms
Anti-viral and Apoptotic Induction of m-TOR Inhibitor Drugs against Hepatitis C Virus Activity and Hepatocellular Carcinoma Cell Line: In vitro and in silico. (PubMed, Asian Pac J Cancer Prev)
Overall, this study provides encouraging evidence for the potential of m-TOR inhibitor drugs as promising therapeutic agents for both HCC and HCV, warranting further investigation and optimization for clinical applications.
Preclinical • Journal
|
mTOR (Mechanistic target of rapamycin kinase) • TNFA (Tumor Necrosis Factor-Alpha) • FASLG (Fas ligand) • CASP3 (Caspase 3) • CASP8 (Caspase 8)
|
FASLG elevation
|
everolimus
2ms
mTOR inhibitor in the treatment of TFE-positive advanced maligmnant PEComa of the uterus: a case report and literature review. (PubMed, Ginekol Pol)
The patient described herein had a TFE-positive uterine malignant PEComa with lung metastasis and responded well to the mTOR inhibitor, everolimus. Close follow-up in the last 3 years showed remission without recurrence or progression.
Review • Journal • Metastases
|
TSC1 (TSC complex subunit 1)
|
everolimus
2ms
RESTOR: PK/PD mTORi Inhibition in Older Adults (clinicaltrials.gov)
P1, N=194, Not yet recruiting, The University of Texas Health Science Center at San Antonio
New P1 trial
|
ICAM1 (Intercellular adhesion molecule 1)
|
everolimus • sirolimus
2ms
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL (clinicaltrials.gov)
P1, N=45, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Sep 2024 --> Apr 2025
Trial completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
everolimus • Kisqali (ribociclib) • dexamethasone